Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Multiple Sclerosis, Relapsing-Remitting

abstract

  • Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). In clinical trials and off-label use in MS, alemtuzumab has been administered intravenously (IV). Alemtuzumab is approved for chronic lymphoid leukemia as IV. Oncology guidelines recommend alemtuzumab subcutaneous (SC) over IV. There is no report of alemtuzumab SC in MS. We report two patients with highly active relapsing MS who were treated with SC alemtuzumab, had significant improvement and tolerated SC alemtuzumab well without the typical infusion-associated adverse events. SC alemtuzumab in MS warrants further studies as this may enhance patient convenience and minimize infusion-associated adverse events.

publication date

  • August 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1177/1352458511435716

PubMed ID

  • 22252465

Additional Document Info

start page

  • 1197

end page

  • 9

volume

  • 18

number

  • 8